Favipiravir Therapy in Adults With Mild COVID-19

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

July 23, 2020

Primary Completion Date

August 4, 2021

Study Completion Date

August 4, 2021

Conditions
COVID-19
Interventions
DRUG

Favipiravir

1800 mg twice daily for one day, followed by 800mg (4 tablets) twice daily

DRUG

Placebo

(9 tablets) by mouth twice daily for one day, followed by (4 tablets) twice daily (Maximum days of therapy is 7 days)

Trial Locations (7)

Unknown

King Fahad Hospital - Madinah, Al Madīnah

Primary Health Care-Safiyah, Al Madīnah

Prince Mohammed Bin Abdul Aziz Hospital - Al Madinah, Al Madīnah

King Abdullah Medical City - Makkah, Mecca

King Abdulaziz Medical City - Riyadh, Riyadh

Primary Health Care-Al Mansoura, Riyadh

Primary Health Care-Al Urijah, Riyadh

All Listed Sponsors
collaborator

Ministry of Health, Saudi Arabia

OTHER_GOV

lead

King Abdullah International Medical Research Center

OTHER

NCT04464408 - Favipiravir Therapy in Adults With Mild COVID-19 | Biotech Hunter | Biotech Hunter